Bismuth Tribromophenate

Summary

Bismuth Tribromophenate (CHEMBL4594616) is a phase-3 clinical-stage unknown; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594616
Name	Bismuth Tribromophenate
Type	Unknown
Max phase	3

Also known as: Bismuth tribromophenate, Dressing, xeroform, Sigmaform, Xeroform, BISMUTH TRIBROMOPHENATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	2
Not specified	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05499104	PHASE3	COMPLETED	A Trial Comparing a Cellulose Dressing to Two Standard of Care Dressings in Treating Split Thickness Donor Sites in Burn and Wound Patients.
NCT00479193	PHASE1	WITHDRAWN	Polymem vs. Bacitracin/Xeroform in Treating Burn Wounds
NCT04323475	PHASE1	UNKNOWN	Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients
NCT03340025	Not specified	COMPLETED	Single-Use Negative Pressure Wound Therapy for Free Flap Donor Sites
NCT04149808	Not specified	WITHDRAWN	Mepilex Ag vs. Xeroform in Pediatric Patients That Sustain Partial Thickness Burn Injury

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).